» 2021-2022 Dentistry Courses » All » Oral/Systemic Connection

Oral/Systemic Connection

Price: 15.00


Location: The University of Utah, School of Dentistry, 530 S. Wakara Way, Salt Lake City, Utah, 84108

Dinner: 6:30 pm to 7:00 pm   Presentation: 7:00 pm to 9:00 pm.

CDE Hours Awarded: 2 CDE Lecture                                     

Conflicts of Interest: No Conflicts

Education Methods: Lecture and AGD subject codes: 010, 730                 

Required Attendee Experience: Dental Practice Experience

External Funding: None

 

David Okano: Featured Speaker #1

Sugar: It’s Not Just for Caries. Too Much in Your Bloodstream Can Also Affect Your Periodontium and Your Health

Periodontal disease is now considered the sixth complication of diabetes mellitus. Learn how the bidirectional relationship between periodontitis and diabetes may have a significant effect upon not only the periodontal tissues but also with an individual’s systemic health. Our role as dental health care providers can lead to improved health outcomes for both the oral cavity and one’s overall health. Learn how to treat diabetic patients to establish not only improved periodontal conditions but better systemic health.

Hour 1 objectives;

  1. Understand how an uncontrolled diabetic condition can affect the periodontal tissues
  2. Understand how treatment of periodontal inflammation in an uncontrolled diabetic may have a positive effect upon the glycemic control of a diabetic patient
  3. Provide periodontal treatment protocols for the diabetic patient

Scott Summers: Featured Speaker #2

The New Cholesterol and other tales from the Utah Diabetes and Metabolism Research Center.

The history of the University of Utah (UofU), the only Academic Medical Center in the Intermountain West, is replete with examples of biomedical research excellence. UofU investigators received the first extramural grant ever awarded by the NIH (Maxwell Wintrobe); transplanted the first artificial heart into a human subject (William DeVries); conducted the definitive, Nobel Prize-winning work on genome modification (Mario Capecchi); developed the Utah Population Database (the only medical registry of its kind); identified key genetic determinants of disease (e.g., BRCA1APC, andKCNH2 mutations in breast cancer, colon cancer, and cardiac arrhythmia, respectively); and made seminal discoveries related to mitochondrial biology, nutrient metabolism, and cardiometabolic disease. Building on this rich history of success, the UofU in 2014 established the Utah Diabetes and Metabolism Research Center (UDMRC), providing the resources and infrastructure to enhance its robust diabetes research community. The Center, which bridges researchers across the translational spectrum, has been highly successful and its collaborative and engaged investigators have made paradigm-shifting advances on the causes and treatments of diabetes and its complications. This presentation by one of the UDMRC co-directors will discuss recent examples of research excellence from this highly successful research center.

Hour 2 objectives;

  1. To understand the etiology of type 1 and type 2 diabetes
  2. To understand how alterations in fat metabolism give rise to diabetes and its complications
  3. To learn about new therapeutics being developed by University of Utah Investigators



Speaker #1

David Okano, D.D.S.;

David Okano was in private practice as a periodontist in Rock Springs, Wyoming for many years prior to his appointment at the University of Utah School of Dentistry.  He currently serves as Section Head of Periodontics.  David received his periodontal training at the University of Nebraska Medical Center College of Dentistry and is a Diplomate of the American Board of Periodontology.  He is a Past-President of the Wyoming Dental Association and currently serves as President-Elect of the American Academy of Periodontology.

Speaker # 2

Scott Summers, Ph.D.;

Professor Summers Chairs the Department of Nutrition and Integrative Physiology and Co-Directs the Diabetes and Metabolism Research Center at the University of Utah. He has been the leading voice advancing the idea that a class of fat molecules termed ceramides drive diabetes and heart disease. Though the idea was initially controversial, the role of ceramides as drivers of pathology is now widely accepted and clinics have started measuring ceramides as a means of assessing disease risk. His work has appeared in the highest impact journals and he has given hundreds of presentations around the globe. Based on his discoveries, he co-founded Centaurus Therapeutics, a biotechnology company that is developing new ceramide-lowering medications to combat the underpinnings of diabetes and heart disease.